Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30119% above fair value
$43.24+0.84 (+1.98%)
Close on Nov 11, 2026Market cap $50.39BP/E 72.1Yield –
Teva Pharmaceutical Industries profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Teva Pharmaceutical Industries's profit margin for the twelve months ending Jun 30, 2026 was 5.0%. For fiscal 2025 it was 8.2%, against -9.9% the year before. The highest annual figure on record is 20.7% in fiscal 2010.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.2% | +18.1 |
| FY2024 | Dec 31, 2024 | -9.9% | −6.4 |
| FY2023 | Dec 31, 2023 | -3.5% | +12.9 |
| FY2022 | Dec 31, 2022 | -16.4% | −19.0 |
| FY2021 | Dec 31, 2021 | 2.6% | +26.6 |
| FY2020 | Dec 31, 2020 | -24.0% | −18.0 |
| FY2019 | Dec 31, 2019 | -5.9% | +5.9 |
| FY2018 | Dec 31, 2018 | -11.8% | +62.7 |
| FY2017 | Dec 31, 2017 | -74.4% | −75.9 |
| FY2016 | Dec 31, 2016 | 1.5% | −6.6 |
| FY2015 | Dec 31, 2015 | 8.1% | −7.0 |
| FY2014 | Dec 31, 2014 | 15.1% | +8.8 |
| FY2013 | Dec 31, 2013 | 6.2% | −3.4 |
| FY2012 | Dec 31, 2012 | 9.7% | −5.4 |
| FY2011 | Dec 31, 2011 | 15.1% | −5.6 |
| FY2010 | Dec 31, 2010 | 20.7% | +8.3 |
| FY2009 | Dec 31, 2009 | 12.4% | +6.9 |
| FY2008 | Dec 31, 2008 | 5.5% | −14.9 |
| FY2007 | Dec 31, 2007 | 20.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -13.9% | −20.7 |
| Q1 FY2026 | Mar 31, 2026 | 9.3% | +3.8 |
| Q4 FY2025 | Dec 31, 2025 | 32.0% | +37.1 |
| Q3 FY2025 | Sep 30, 2025 | 9.7% | +19.8 |
| Q2 FY2025 | Jun 30, 2025 | 6.8% | +27.1 |
| Q1 FY2025 | Mar 31, 2025 | 5.5% | +9.1 |
| Q4 FY2024 | Dec 31, 2024 | -5.1% | −15.5 |
| Q3 FY2024 | Sep 30, 2024 | -10.1% | −11.9 |
| Q2 FY2024 | Jun 30, 2024 | -20.3% | +2.2 |
| Q1 FY2024 | Mar 31, 2024 | -3.6% | +2.4 |
| Q4 FY2023 | Dec 31, 2023 | 10.4% | +43.9 |
| Q3 FY2023 | Sep 30, 2023 | 1.8% | +0.1 |
| Q2 FY2023 | Jun 30, 2023 | -22.5% | −15.9 |
| Q1 FY2023 | Mar 31, 2023 | -6.0% | +20.1 |
| Q4 FY2022 | Dec 31, 2022 | -33.5% | −29.6 |
| Q3 FY2022 | Sep 30, 2022 | 1.7% | −5.8 |
| Q2 FY2022 | Jun 30, 2022 | -6.6% | −11.9 |
| Q1 FY2022 | Mar 31, 2022 | -26.1% | −28.0 |
| Q4 FY2021 | Dec 31, 2021 | -3.9% | −7.2 |
| Q3 FY2021 | Sep 30, 2021 | 7.5% | +116.8 |
| Q2 FY2021 | Jun 30, 2021 | 5.3% | +1.7 |
| Q1 FY2021 | Mar 31, 2021 | 1.9% | +0.4 |
| Q4 FY2020 | Dec 31, 2020 | 3.4% | +0.9 |
| Q3 FY2020 | Sep 30, 2020 | -109.3% | −101.7 |
| Q2 FY2020 | Jun 30, 2020 | 3.6% | +20.1 |
| Q1 FY2020 | Mar 31, 2020 | 1.6% | +4.1 |
| Q4 FY2019 | Dec 31, 2019 | 2.5% | +67.8 |
| Q3 FY2019 | Sep 30, 2019 | -7.7% | −2.9 |
| Q2 FY2019 | Jun 30, 2019 | -16.5% | −12.6 |
| Q1 FY2019 | Mar 31, 2019 | -2.5% | −25.3 |
| Q4 FY2018 | Dec 31, 2018 | -65.3% | +148.4 |
| Q3 FY2018 | Sep 30, 2018 | -4.7% | −15.3 |
| Q2 FY2018 | Jun 30, 2018 | -3.9% | +100.5 |
| Q1 FY2018 | Mar 31, 2018 | 22.8% | +11.4 |
| Q4 FY2017 | Dec 31, 2017 | -213.7% | −198.7 |
| Q3 FY2017 | Sep 30, 2017 | 10.6% | +3.2 |
| Q2 FY2017 | Jun 30, 2017 | -104.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 11.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -15.0% | – |
| Q3 FY2016 | Sep 30, 2016 | 7.4% | – |
See a number that looks wrong?